PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

OSI Pharmaceuticals to Give Talk At Protein Kinases Meeting May 27-28 in Boston - Andrew Crew, Director of Cancer Chemistry at OSI Pharmaceuticals to speak at GTCbio’s 5th Protein Kinases in Drug Discovery conference May 27-28, in Boston, Massachusetts
OSI Pharmaceuticals to Give Talk At Protein Kinases Meeting May 27-28 in Boston

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2010/03/15 - Andrew Crew, Director of Cancer Chemistry at OSI Pharmaceuticals to speak at GTCbio’s 5th Protein Kinases in Drug Discovery conference May 27-28, in Boston, Massachusetts.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Andrew Crew will give a presentation on “Imidazo[1,5-a]pyrazines: Selective and Orally Efficacious mTORC1/2 Inhibitors” at the 5th Annual Protein Kinases in Drug Discovery conference to be held this year in Boston, MA on May 27-28, 2010 by GTCbio. The presentation will describe the identification of a series of imidazo[1,5-a]pyrazines that, through a combination of empirical medicinal chemistry exploration and use of a PI3K?-derived homology model, provided potent and selective inhibitors of both mTORC1 and mTORC2 with broad spectrum anti-tumor activity in vivo.

Benefits of Dr. Crew’s presentation include:

- Description of SAR within the imidazopyrazine series;
- Control of in vitro ADMET properties;
- Optimization of oral PK;
- Demonstration of efficacy in multiple xenograft models.

Andy Crew joined OSI in 2002 and has been the multidisciplinary project team leader for OSI’s c-Kit/KDR and mTORC1/2 kinase projects culminating in the development/clinical agents OSI-930, OSI-817 and OSI-027. Currently he is co-head of the OSI Cancer Chemistry department in NY with leadership oversight for multiple advanced and exploratory projects, external collaborations and computational chemistry.

Prior to OSI, Andy worked at Tularik Ltd. (formerly Protherics Molecular Design Ltd) for 6 years, where he worked on the structure-based design and synthesis of inhibitors of the serine proteases factors Xa and VIIa, urokinase and tryptase. Prior to Tularik, Andy worked at Knoll-BASF Pharma (formerly Boots Pharmaceuticals) for 6 years working on neurological diseases, specifically on the discovery of dopamine D1/D5 receptor antagonists, and D2 antagonist/5-HT1A agonist approaches as atypical antipsychotics for the treatment of schizophrenia.

Andy received his Ph.D. in Organic Chemistry in 1991 from the University of Liverpool, UK under Dr. Dick Storr working on “Approaches to Heterocyclic Analogues of o-Xylylene.”
He received his BSc degree (First Class Hons) in Applied Chemistry in 1987 from the University of Wales Institute of Science and Technology in Cardiff, UK.

Also presenting at the Protein Kinase conference are prestigious organizations including AstraZeneca, Bristol-Myers Squibb, Dana-Farber, Dartmouth, Genentech, GlaxoSmithKline, Harvard, Roche, Merck, Pfizer, Tufts, UCSD, Wyeth and other leaders in the kinase industry.

The 5th Protein Kinases in Drug Discovery conference features presentations on new technology for kinase target and inhibitor identification and screening, kinase selectivity, kinase drug design, kinase targets & inhibitors in oncology, kinase targets & inhibitors in CNS disorders, and kinase targets & inhibitors in inflammatory disorders.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


OSI Pharmaceuticals to Give Talk At Protein Kinases Meeting May 27-28 in Boston

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  SKS Media | SKS Associates Ltd

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)